March 24, 2017
Bivarus Raises $4 Million to Fuel Continued Growth
March 21, 2017 — DURHAM, N.C. — Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience and employee engagement, announced today it raised $4 million in a Series B from existing investors. Hatteras Venture Partners led this latest financing round. Other participants in the round include Excelerate Health Ventures, Nashville-based NueCura Partners and Boston Millennia Partners.
February 28, 2017
Hatteras Venture Partners Announces Launch of the Venture Capital Multiplier Fund
February 28, 2017 – DURHAM, NC – As announced previously by former Governor McCrory, Hatteras Venture Partners was selected by the State of North Carolina as the manager of the Venture Capital Multiplier Fund, LP (VCMF). The VCMF has $60 million in capital. A portion of the VCMF has been committed to the latest Hatteras venture capital fund, Hatteras Venture Partners V, LP (HVP V).
January 18, 2017
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), a Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.
January 6, 2017
Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis
RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail. Onychomycosis is a chronic fungal infection involving the nail, nail bed, and surrounding tissues. VT-1161, the company’s lead product candidate, is a highly potent and selective orally available inhibitor of fungal CYP51.
January 6, 2017
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), a Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.
January 5, 2017
Hatteras Venture Partners Announces the Final Closing of Hatteras Venture Partners V, LP
DURHAM N.C., January 5, 2017 – Hatteras Venture Partners announced today the final closing of Hatteras Venture Partners V (HVP V) with over $150 million in total capital. Hatteras will continue its strategy of building great companies in the human medicine life sciences by investing at the seed and early stage. Like HVP IV, the firm will allocate a portion of HVP V to Hatteras Discovery to expand its successful model of company formation.